TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34027894

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP, unit = 10 mmHg)
Number of subjects: 141
Study: 34027998

Group type: EXPERIMENTAL
Intervention: pyrethroid-PBO nets
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: unwashed pyrethroid-PBO nets
Number of subjects: 16

Group type: COMPARATOR
Intervention: washed pyrethroid-PBO nets
Number of subjects: 16
Study: 34028393

Group type: EXPERIMENTAL
Intervention: Novel 5-strain probiotic blend (Bl-04, Bi-07, HN019, NCFM, Lpc-37) administered once daily for 30 days
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Novel 5-strain probiotic blend
Number of subjects: 188
Study: 34028627

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 398
Study: 34028703

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1211
Study: 34028701

Group type: EXPERIMENTAL
Intervention: Subclinical AKI (KDIGO negative AND NGAL/hepcidin-25 ratio-positive)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Combined AKI (KDIGO positive AND NGAL/hepcidin-25 ratio-positive)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Clinical AKI (KDIGO positive AND NGAL/hepcidin-25 ratio-negative)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Subclinical AKI
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Combined AKI
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Pooled subclinical and clinical AKI
Number of subjects: 198
Study: 34028812

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 30412

Group type: COMPARATOR
Intervention: Active treatment
Number of subjects: 30412
Study: 34029273

Group type: EXPERIMENTAL
Intervention: Quantitative pupillometry (QP) measures including percentage pupil constriction (CONQ), minimum pupillary diameter (MIN), and maximum pupillary diameter (MAX)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Predictive model including minimum pupillary diameter 3 minutes after morphine administration (MIN3), minimum pupillary diameter normalized to baseline (MIN31), and percentage pupillary constriction after surgery (T4) standardized to baseline (T1) (CONQ41) along with weight-based morphine dose
Number of subjects: 220
Study: 34029345

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine assessment through the HeartlineTM mobile application
Number of subjects: 9106
Study: 34029377

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (oral calcifediol at days 1, 3, and 7; single high dose of oral cholecalciferol at baseline)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (daily doses for at least 14 days, continued weekly if vitamin D blood levels > 50 ng/mL)
Number of subjects: 356
Study: 34029490

Group type: EXPERIMENTAL
Intervention: Plasma cortisol level after a 1-mg dexamethasone suppression test
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Cortisol levels
Number of subjects: 1048
Study: 34029566

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEis) and angiotensin-receptor blockers (ARBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonusers of ACEis and ARBs
Number of subjects: 0
Study: 34029994

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG-interferon-α-based therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Host-targeting strategies
Number of subjects: 0
Study: 34030162

Group type: EXPERIMENTAL
Intervention: Therapeutic approaches to modulate intestinal microbiota (dietary interventions, probiotic administration, fecal microbiota transplantation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbiota modulators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34030173

Group type: EXPERIMENTAL
Intervention: Central Sensitization Inventory (CSI) score ≥ 40
Number of subjects: 335

Group type: COMPARATOR
Intervention: Central Sensitization Inventory (CSI) score < 40
Number of subjects: 335
Study: 34030430

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 80
Study: 34030643

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID
Number of subjects: 97
Study: 34030695

Group type: EXPERIMENTAL
Intervention: Progressive fibrosing interstitial lung disease (PF-ILD) patients
Number of subjects: 14413
Study: 34030698

Group type: EXPERIMENTAL
Intervention: Mini-sternotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mini-thoracotomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34030728

Group type: EXPERIMENTAL
Intervention: Perioperative serum creatinine (sCr) measurement
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Long-term kidney function assessment
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Physician survey on sCr measurement
Number of subjects: 423
Study: 34030986

Group type: EXPERIMENTAL
Intervention: Oral azithromycin, ethambutol, and rifampin (simultaneous doses in fasting state and with food and pancreatic enzymes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fasting doses of azithromycin, ethambutol, and rifampin
Number of subjects: 30
Study: 34031050

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment
Number of subjects: 67
Study: 34031051

Group type: EXPERIMENTAL
Intervention: Intravenous isavuconazonium sulfate (10 mg/kg body weight, maximum 372 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oral isavuconazonium sulfate (10 mg/kg body weight, maximum 372 mg)
Number of subjects: 46
Study: 34031134

Group type: EXPERIMENTAL
Intervention: CLIP intervention (≥8 contacts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (usual care)
Number of subjects: 0
Study: 34031380

Group type: EXPERIMENTAL
Intervention: Partially attenuated rDEN2Δ30 challenge virus
Number of subjects: 0
Study: 34031508

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) of the anterior faucial pillar region
Number of subjects: 30
Study: 34031519

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with severe pneumonia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-COVID-19 patients with severe pneumonia
Number of subjects: 61
Study: 34031756

Group type: EXPERIMENTAL
Intervention: LY01610 (liposome-encapsulated irinotecan) administered intravenously every 2 weeks, with the first cycle in dose escalation being 3 weeks.
Number of subjects: 24
Study: 34031762

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (RAS)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 371

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 371
Study: 34031858

Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry and capnography monitoring
Number of subjects: 2447

Group type: COMPARATOR
Intervention: Intermittent pulse oximetry
Number of subjects: 2447
Study: 34031871

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 112

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 112
Study: 34032031

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Kidney transplantation (early intervention)
Number of subjects: 81
Study: 34032202

Group type: EXPERIMENTAL
Intervention: Hypersomnia Severity Index (HSI)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: HSI-S cutoff score
Number of subjects: 158
Study: 34032468

Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) combined with Clinical Risk Factors (CRFs)
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Clinical Risk Factors (CRFs) alone
Number of subjects: 1617

Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) alone
Number of subjects: 1617
Study: 34032575

Group type: EXPERIMENTAL
Intervention: Deep South IVR System-Supported Active Lifestyle intervention (IVR-automated physical activity-related phone counseling)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 240
Study: 34032578

Group type: EXPERIMENTAL
Intervention: My Diabetes Care (MDC) intervention
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study: 34032584

Group type: EXPERIMENTAL
Intervention: BUBOlight device (phototherapy) for 4-hour session of illumination
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BUBOlight device (phototherapy)
Number of subjects: 10
Study: 34032893

Group type: EXPERIMENTAL
Intervention: piggyBac-generated EGFR-CAR T cells
Number of subjects: 9
Study: 34032932

Group type: EXPERIMENTAL
Intervention: Non-invasive central blood pressure assessment using an oscillometric automated device (Mobil-O-Graph)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Invasive blood pressure assessment by radial arterial cannulation
Number of subjects: 100
Study: 34033120

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Bifonazole cream
Number of subjects: 559

Group type: COMPARATOR
Intervention: Bifonazole solution
Number of subjects: 559
Study: 34033178

Group type: EXPERIMENTAL
Intervention: Personalized intervention (aerobic exercise program at 60-85% HRR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control intervention (aerobic exercise program at 20-40% HRR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups received standard behavioral support and nicotine replacement therapy
Number of subjects: 150
Study: 34033266

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray
Number of subjects: 175
Study: 34033596

Group type: EXPERIMENTAL
Intervention: Timed-up-and-go (TUG) test
Number of subjects: 49
Study: 34033803

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-guided intervention to detect atrial fibrillation (AF) using a monitoring device mailed to patients for continuous monitoring for up to 30 days.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-guided intervention to detect atrial fibrillation (AF) using a monitoring device.
Number of subjects: 1000
Study: 34033835

Group type: EXPERIMENTAL
Intervention: Diabetic older adults
Number of subjects: 515

Group type: COMPARATOR
Intervention: Amino acids (independent of diabetes status)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Nitrogen handling pathways
Number of subjects: 515
Study: 34034272

Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (DCNN) for polyp detection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (baseline detection without DCNN)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DCNN
Number of subjects: 42
Study: 34034693

Group type: EXPERIMENTAL
Intervention: Peer co-delivered vocational rehabilitation services
Number of subjects: 46
Study: 34034699

Group type: EXPERIMENTAL
Intervention: Increased availability of lower energy main dishes (50%)
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Energy labelling
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Baseline availability of lower energy main dishes (10%)
Number of subjects: 2091
Study: 34034772

Group type: EXPERIMENTAL
Intervention: Malreduction criteria (TF overlap)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Malreduction criteria (dime sign)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Malreduction criteria (tibiotalar tilt)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Malreduction criteria (TF widening)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inflammatory cytokine levels
Number of subjects: 46
Study: 34034777

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP) in SARS-CoV-2 patients
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP) in influenza pneumonia patients
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP) in no viral infection patients
Number of subjects: 1576
Study: 34034795

Group type: EXPERIMENTAL
Intervention: CD38-targeted chimeric antigen receptor T (CAR-T-38) cells
Number of subjects: 6
Study: 34035077

Group type: EXPERIMENTAL
Intervention: Intensive glucose control and blood pressure-lowering therapy
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Frailty status (FI >0.21)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering and BP-lowering treatments
Number of subjects: 11140
Study: 34035090

Group type: EXPERIMENTAL
Intervention: Real-world clinical care and outcomes of patients with AMI
Number of subjects: 0
Study: 34035097

Group type: EXPERIMENTAL
Intervention: WARM Hearts study assessments including medical history, body composition, cognition, frailty status, functional fitness, physical activity levels, nutritional status, quality of life questionnaires, sleep behaviour, resting blood pressure, BP response to moderate-intensity exercise, arterial stiffness, heart rate variability, lipid and novel biomarker profiles, gut microbiota characterization.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: WARM Hearts study approaches
Number of subjects: 1000
Study: 34035103

Group type: EXPERIMENTAL
Intervention: Multimodal approach using functional near-infrared spectroscopy (fNIRS), electroencephalography, and heart rate variability via ECG during cognitive tasks (Stroop, N-back, verbal fluency test).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodal approach (fNIRS, EEG, ECG)
Number of subjects: 0
Study: 34035290

Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transfer (AFMT)
Number of subjects: 25
Study: 34035441

Group type: EXPERIMENTAL
Intervention: Microbe culture from anaerobically preserved tissue combined with metagenome sequencing (MC-MGS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culture-based studies with axenic cultures
Number of subjects: 0
Study: 34035477

Group type: EXPERIMENTAL
Intervention: Estradiol-treated (E2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Progesterone-treated (P4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Untreated (steroid-free)
Number of subjects: 24
Study: 34035832

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0
Study: 34035833

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later, with additional as-needed doses after course 2.
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN-alemtuzumab (2 alemtuzumab 12 mg courses after discontinuation of SC IFNB-1a).
Number of subjects: 0
Study: 34036177

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) treatment for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) treatment
Number of subjects: 36
Study: 34036233

Group type: EXPERIMENTAL
Intervention: 31-gene expression profile (31-GEP) test
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: 31-GEP class 2 results
Number of subjects: 323

Group type: COMPARATOR
Intervention: Patients with stage I-IIA CM and a class 2 result
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Combining 31-GEP results and AJCC staging
Number of subjects: 323
Study: 34036343

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 34036426

Group type: EXPERIMENTAL
Intervention: Women with CAD and CKD
Number of subjects: 3352

Group type: COMPARATOR
Intervention: Men with CAD and CKD
Number of subjects: 3352
Study: 34036490

Group type: EXPERIMENTAL
Intervention: Weekly 20% subcutaneous immune globulin (SCIG; Cuvitru, Ig20Gly)
Number of subjects: 0
Study: 34036552

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (100 mg/kg once daily, infused in 30 minutes)
Number of subjects: 45
Study: 34036560

Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Pomalidomide-dexamethasone
Number of subjects: 307
Study: 34037241

Group type: EXPERIMENTAL
Intervention: Capecitabine-containing regimens
Number of subjects: 19934
Study: 34037715

Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg (≥40 kg) or 3 mg/kg (<40 kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ustekinumab 390 mg (≥40 kg) or 9 mg/kg (<40 kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses)
Number of subjects: 44
Study: 34037951

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34037999

Group type: EXPERIMENTAL
Intervention: Functional iron-deficiency treatment, specific details not available
Number of subjects: 0
Study: 34038379

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg 4 times daily for 1 year
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Domperidone treatment
Number of subjects: 62
Study: 34038421

Group type: EXPERIMENTAL
Intervention: P. vivax infection
Number of subjects: 7

Group type: COMPARATOR
Intervention: P. falciparum infection
Number of subjects: 7
Study: 34038556

Group type: EXPERIMENTAL
Intervention: Magnesium Depletion Score (MDS) in PPCCT
Number of subjects: 10077

Group type: COMPARATOR
Intervention: Serum magnesium alone in PPCCT
Number of subjects: 10077

Group type: EXPERIMENTAL
Intervention: MDS in NHANES
Number of subjects: 10077

Group type: EXPERIMENTAL
Intervention: Low magnesium intake in NHANES
Number of subjects: 10077
Study: 34038589

Group type: EXPERIMENTAL
Intervention: SM04690
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 5
Study: 34038699

Group type: EXPERIMENTAL
Intervention: Early bacterial identification
Number of subjects: 0
Study: 34038916

Group type: EXPERIMENTAL
Intervention: Genicular nerve block
Number of subjects: 70

Group type: COMPARATOR
Intervention: Local infiltration analgesia
Number of subjects: 70
Study: 34039015

Group type: EXPERIMENTAL
Intervention: Bare and Covered Cheatham-Platinum Stents
Number of subjects: 248
Study: 34039021

Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 34039031

Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) as a continuous variable
Number of subjects: 12792

Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS) as a categorical variable (highest tertile)
Number of subjects: 12792

Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 12792

Group type: EXPERIMENTAL
Intervention: Conventional model plus PRS
Number of subjects: 12792

Group type: EXPERIMENTAL
Intervention: Continuous PRS
Number of subjects: 12792

Group type: EXPERIMENTAL
Intervention: Continuous net reclassification index after adding PRS to the conventional model
Number of subjects: 12792
Study: 34039285

Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma uric acid (PUA) (373 µmol/l)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Lowest quartile of plasma uric acid (PUA) (234 µmol/l)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: PUA concentration
Number of subjects: 606
Study: 34039337

Group type: EXPERIMENTAL
Intervention: Health care professionals (HCP) perspectives on spiritual concerns and needs
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Chronic pain patients (CPP) perspectives on spiritual concerns and needs
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Commonalities and differences in perspectives of HCPs and CPPs
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Need for training and awareness
Number of subjects: 76
Study: 34039438

Group type: EXPERIMENTAL
Intervention: Blended therapy (interactive tablet-based home exercise program combined with face-to-face therapy sessions)
Number of subjects: 14
Study: 34039578

Group type: EXPERIMENTAL
Intervention: Caregiver assessments after the death of the individual with DLB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terminal trend models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver factors assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative descriptive analysis
Number of subjects: 0
Study: 34039647

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 24
Study: 34039905

Group type: EXPERIMENTAL
Intervention: Guided self-rehabilitation contracts (GSCs) combined with abobotulinumtoxinA injections (1500 U)
Number of subjects: 153
Study: 34039929

Group type: EXPERIMENTAL
Intervention: Multimodal educational intervention in targeted normoxia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34039930

Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case (BC/WC) communication tool
Number of subjects: 86
Study: 34040174

Group type: EXPERIMENTAL
Intervention: Berzosertib (90-210 mg) plus cisplatin (day 1) every 3 weeks (Q3W)
Number of subjects: 31
Study: 34040175

Group type: EXPERIMENTAL
Intervention: berzosertib + gemcitabine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: berzosertib + gemcitabine + cisplatin
Number of subjects: 60
Study: 34040195

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GHT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNORD116 deletion (in knockout mouse model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iPSC-derived neurons from a SNORD116-deleted PWS patient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34040400

Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (600-800 mg three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen (375-500 mg twice daily)
Number of subjects: 0
Study: 34040605

Group type: EXPERIMENTAL
Intervention: Intracerebral gene therapy with recombinant AAV serotype 2/5 (rAAV2/5) coding human NAGLU
Number of subjects: 4
Study: 34040886

Group type: EXPERIMENTAL
Intervention: Yoga intervention (24 sessions over 12 weeks)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 202
Study: 34041280

Group type: EXPERIMENTAL
Intervention: Acute Insulin Resistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-insulin resistant patients)
Number of subjects: 0
Study: 34041284

Group type: EXPERIMENTAL
Intervention: Serum homocysteine level
Number of subjects: 0